Journal profile · ONCOLOGY
Blood and Lymphatic Cancer-Targets and Therapy
ISSN 1179-9889 · Dove Medical Press · United Kingdom
Blood and Lymphatic Cancer-Targets and Therapy: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.4 (journal website); JCR Q2 (journal website); fully open access; APC about USD 3,565; median 105 days to acceptance (39 articles, last 24 months); acceptance rate 21% (journal website); 19 articles in 2025; indexed in ESCI.
Scope
Aims, scope and focus
Blood and Lymphatic Cancer-Targets and Therapy is published by Dove Medical Press and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and Acute Myeloid Leukemia Research, together about 36.8% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr Wilson Gonsalves Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Blood and Lymphatic Cancer: Targets and Therapy will no longer consider meta-analyses for publication. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations Updated 16 July 2025
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Gonsalves DivisionPublisher website
Editorial board by country: 2 in mainland China (about 9%); most named United States 7, Italy 6, Mainland China 2, Taiwan, China 2, Japan 2 (23 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine16.1%
- Chronic Lymphocytic Leukemia ResearchMedicine11.6%
- Acute Myeloid Leukemia ResearchMedicine9.1%
- Acute Lymphoblastic Leukemia researchMedicine8.2%
- Multiple Myeloma Research and TreatmentsMedicine6.7%
- Chronic Myeloid Leukemia TreatmentsMedicine6.4%
- CAR-T cell therapy researchMedicine4.6%
- CNS Lymphoma Diagnosis and TreatmentMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 4.4Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.4Publisher website ·
- h-index
- 18OpenAlex ·
- i10-index
- 39OpenAlex ·
- 2-year mean citedness
- 1.15OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 96.67%LetPub ·
Volume
- Articles per year
- 17LetPub ·
- Downloads per year (publisher)
- 22,500Publisher website ·
Articles by year OpenAlex count · 149 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 22 | 22 | 3 |
| 2025 | 19 | 19 | 19 |
| 2024 | 6 | 6 | 32 |
| 2023 | 7 | 7 | 79 |
| 2022 | 12 | 12 | 289 |
| 2021 | 6 | 6 | 105 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
105 daysMedian, submission to acceptance · P25–P75 88 days – 129 days
- Acceptance to online
- median 11 days (39 articles)
- Submission to online
- median 121 days
- Sample
- 39 articles with submission and acceptance dates (42 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 21%Publisher website ·
- Desk decision
- 40 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,565 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics
Member of and subscribes to the principles of the Committee on Publication Ethics (COPE) Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1179-9889
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Blood and Lymphatic Cancer-Targets and Therapy
What CAS zone is Blood and Lymphatic Cancer-Targets and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Blood and Lymphatic Cancer-Targets and Therapy is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Blood and Lymphatic Cancer-Targets and Therapy?
The journal's website gives an impact factor of 4.4 (2025); this is the journal's own figure, as LetPub lists none for it; h-index 18.
How long does peer review take at Blood and Lymphatic Cancer-Targets and Therapy?
Based on the dates recorded on 39 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 105 days (interquartile range 88–129 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 21%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Blood and Lymphatic Cancer-Targets and Therapy in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Medicine.
Where are the editorial board members of Blood and Lymphatic Cancer-Targets and Therapy based?
Of the 23 board members whose country the journal's board page names, 2 (about 9%) are in mainland China; the countries named most often are United States (7), Italy (6) and Mainland China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Blood and Lymphatic Cancer-Targets and Therapy?
According to LetPub and DOAJ records, Blood and Lymphatic Cancer-Targets and Therapy is indexed in ESCI and DOAJ.
Is Blood and Lymphatic Cancer-Targets and Therapy open access, and what is the APC?
Blood and Lymphatic Cancer-Targets and Therapy is a fully open-access journal. APC about USD 3,565.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .